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Multiple randomized controlled trials (RCTs) have shown all NOACs to be equivalent to standard warfarin therapy, with equivocal or reduced rates of stroke 6, 7 and comparable rates of arterial embolism. 8, 9 Bleeding complications have been shown to be similar between the two medications but significantly reduced rates of intracerebral hemorrhage and overall mortality have been documented following the use of NOACs. 2, 10, 11 Consequently, after many years with only one treatment option available, the NOACs now provide a safe alternative to warfarin. Listed below are the current NOAC licenses (UK):
• Dabigatran: for stroke prevention in patients with AF + one CHADS (congestive heart failure, hypertension, age =75 years, diabetes mellitus, stroke) risk factor (150 mg twice daily [BD] ), the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) after parenteral anticoagulation for 5-10 days (150 mg BD), and prevention of VTE in elective hip/knee surgery (110 mg 1-4 hours after surgery, then 220 mg once daily [OD] 9/7).
• Rivaroxaban: for prevention of VTE in elective hip/knee surgery (10 mg OD), stroke prevention in patients with AF + one CHADS risk factor (20 mg OD), and treatment of DVT and PE (15 mg BD), or prophylaxis after recurrent DVT/PE (20 mg OD).
• Apixaban: for prevention of VTE in elective hip/knee surgery (2.5 mg) and stroke prevention in patients with AF + one CHADS risk factor (5 mg).
The European Society of Cardiology and the American Heart Association (AHA) updated their guidelines in 2012 and 2014, respectively, to include NOACs in the management of AF. 12, 13 The American College of Chest Physicians followed in 2012 by advising the use of NOACs for the treatment for VTE, 14 and licenses for all the aforementioned have been approved by the National Institute of Clinical Excellence (NICE).
Edoxaban is the newest inhibitor of factor Xa to complete Phase III trials. It was developed by Daiichi Sankyo, and gained its first license in Japan in 2011 for the prevention of VTE after lower limb surgery. 15 Following the clinical license of dabigatran, rivaroxaban, and apixaban, both the US and the UK have more recently approved edoxaban for the prevention of AF-related strokes and VTE.
Phase I studies concluded that single doses from 10 up to 150 mg, and multiple doses up to 120 mg, were safe and well tolerated. Following multiple Phase II studies, the two key Phase III studies, ENGAGE F-TIMI 16 and Hokusai VTE, 17 have been key in the introduction of edoxaban into clinical practice.
Pharmacokinetics
Edoxaban is a direct factor Xa inhibitor, with a predictable anticoagulation profile. Its peak effects are seen within 1-2 hours, and studies have shown elevated baseline levels for up to 24 hours after administration (half-life 10-14 hours). 18 Although once-daily and twice-daily dosing regimens have been trialed, greater bleeding risks were associated with twice-daily prescriptions. 19 Edoxaban is predominantly eliminated in feces and urine, but renal elimination ranges from 35% to 50%. 18 In patients with renal impairment, dose reduction should also be considered.
20 Table 1 provides summary information of edoxaban. 
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The use of edoxaban in stroke and VTE Although edoxaban has minimal drug and food interactions, it is affected by drugs that inhibit the p-glycoprotein (P-gp) transport protein. Consequently, when taken in combination with such drugs, a dose reduction of 50% is recommended.
21
Efficacy in stroke prevention
AF is one of the most prevalent cardiac conditions, associated with a four to five times increased relative risk of ischemic stroke. 22 Consequently, oral anticoagulant therapies have been used in patients with nonvalvular AF for many years, and they are recommended in all those who have had a prior stroke or transient ischemic attack, or have an increased risk of ischemic event determined by the CHAD 2 S 2 -VASc score. 23 There have been four major RCTs comparing edoxaban to warfarin in the prevention of stroke in nonvalvular AF. Results of these studies are summarized in Tables 2 and 3 . All the RCTs included patients with nonvalvular AF and CHAD 2 S 2 -VASc score of >1. 24, 25 However, the key study so far assessing the use of edoxaban in AF-related stroke prevention is the ENGAGE-AF TIMI 48 trial. 16 This study included 21,105 patients who were randomized to 30 or 60 mg edoxaban OD, compared to standardized warfarin therapy, for 3-12 months. The study was randomized, double blinded, and included patients with a moderate-to-high risk of stroke (CHADS 2 score ≥2). Results showed that both 30 and 60 mg doses of edoxaban were noninferior to warfarin in the prevention of stroke and systemic embolism. Study outcomes are tabulated in Table 3 .
In light of these results, the ENGAGE-AF TIMI 48 trial conclusions recommended edoxaban 60 mg for the prevention of AF-related strokes and 30 mg for those patients with high bleeding risk.
Efficacy in prevention of VTE
VTE most commonly presents as either a DVT or PE and has an estimated mortality of up to 25,000 deaths annually in the UK. 26 It also costs the National Health Service approximately £640 million per year. 27 In light of this, prophylactic subcutaneous low-molecular-weight heparin has been recommended by the National Institute of Clinical Excellence for the prevention of VTE in all those at risk. 28 Three Phase III clinical trials have evaluated the use of edoxaban in the prevention of VTE, including a combined total of 1,418 patients (Table 4) . STARS E-3, STARS J-4, and STARS J-V were all randomized, double-blinded studies in patients undergoing orthopedic surgery, and they compared edoxaban 30 mg once daily to enoxaparin 20 mg twice daily. All three RCTs showed no significant difference in bleeding rates between the two treatments, and both STARS E-3 and 
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The use of edoxaban in stroke and VTE STARS J-V proved edoxaban to be superior in the prevention of VTE. 29, 30 Robertson et al 31 reviewed a total of 27,945 patients (from eleven RCTs) and demonstrated a similar rate of recurrent DVT with the use of edoxaban compared to enoxaparin. A lower rate of recurrent DVT was also observed.
The results of the RCT STARS E-3 29 compared 716 patients following knee arthroscopy and showed edoxaban to be superior to enoxaparin in the prevention of DVT (overall risk reduction of 6.5%).
STARS J-4 compared edoxaban to enoxaparin following trochanteric and subtrochanteric fractures. 32 Rates of VTE with edoxaban and enoxaparin were 6.5% and 3.7%, respectively, and bleeding rates were 3.4% and 6.9%.
Patients undergoing elective, unilateral total knee arthroplasty were compared in the STARS J-V RCT. 30 Six hundred and ten patients were randomized, and outcomes showed edoxaban to be superior to enoxaparin in both prevention of DVT and major bleeding risk.
Efficacy in treatment of VTE
For the treatment of VTE, the largest randomized, doubleblinded Phase III clinical trial is the Hokusai VTE study. 17 This study evaluated whether 5 days of heparin treatment followed by 60 mg once-daily edoxaban would be a superior alternative to warfarin therapy for the prevention of recurrent thromboembolism.
In patients with VTE (including PE with right ventricular dysfunction), treatment with heparin followed by oral edoxaban 60 mg once daily was shown to be noninferior to the standard treatment. With respect to bleeding, results were superior for edoxaban: 8.5% vs 10.3% (P=0.004).
Hokusai VTE also showed that a reduced dose (30 mg OD) of edoxaban is safe in patients with renal impairment and low body weight. Results are summarized in Table 5 .
Safety
As described earlier, the clinical trials of edoxaban efficacy have also reported on the drug safety profile. In combination with the results of large meta-analyses (Table 6) , edoxaban has been shown to be safe in the current recommended doses.
Because of the pharmacokinetics of NOACs, there are no suitable reversal therapies in the setting of acute bleeding. 33, 34 Thus, the same protocol as for major bleeding in warfarin must be adhered to: discontinue the drug, apply manual compression, maintain blood pressure, surgical/ radiological intervention if appropriate, and replace blood products ± prothombin complex concentrate. 35 It is possible 
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Hurst et al to administer activated charcoal orally if the anticoagulant was taken within 2 hours. Tranexamic acid should also be considered following the result of the CRASH-2 trial.
35,36
Conclusion
The NOACs are quickly becoming the preferred treatment in the prevention and management of thromboembolic disease. Edoxaban is a once-daily oral factor Xa inhibitor with fast onset and the added benefit of fixed anticoagulation profiling without routine monitoring. Phase III clinical trials for its use in AF-related strokes (ENGAGE AF-TIMI 48) and VTE treatment (Houkusai VTE) have shown noninferior efficacy compared to standard therapy, as well as reduced rates of bleeding and cardiovascular death. Further studies have also confirmed safe use in both 30 and 60 mg doses.
From the results of multiple RCTs and systematic reviews, edoxaban appears to be a safe and effective alternative treatment to oral coagulation in the clinical setting. However, further developments are always pending. In October 2015, we saw the introduction of the first reversal agent for dabigatran "Praxbind" (idarucizumab; Boehringer Ingelheim, Ingelheim, Germany), and pharmaceutical companies are trialing reversal agents for the factor Xa inhibitors. There are now multiple new options for the management of acute and chronic medical conditions for which we previously could only realistically recommend warfarin in the long term. The focus of clinical trials on both safety and efficacy has facilitated the expansion of edoxaban in clinical practice.
Of the NOACs, edoxaban appears to have the best evidence base for efficacy and safety. The NOACs are here to stay, and physicians and surgeons alike need to learn how to use them optimally for patient safety and benefit.
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